<DOC>
	<DOCNO>NCT00481663</DOCNO>
	<brief_summary>A study different dose MK-0431 participant type 2 diabetes mellitus . There 3 extension base study ( Extension 1 : Week 52 , Extension 2 : Week 106 , Extension 3 : Week 158 ) . The primary hypothesis study In participant type 2 diabetes inadequate glycemic control , 12 week treatment , dose-response see across once-daily dos MK-0431 lower hemoglobin A1C ( HbA1c ) .</brief_summary>
	<brief_title>A Study Different Doses Sitagliptin ( MK-0431 ) Participants With Type 2 Diabetes Mellitus ( MK-0431-014 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Men nonpregnant woman Fasting plasma glucose &gt; = 130 mg/dL HbA1c &gt; =6.5 % &gt; 10.0 % You history type I diabetes You weight loss program ongoing weight loss take weight loss medication You surgery within 30 day You hvae hepatitis B C .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>